EE200300551A - Adenosiini ja selle analoogide kasutamine ravimi valmistamiseks insuliiniresistentsuse sündroomi jadiabeedi raviks - Google Patents

Adenosiini ja selle analoogide kasutamine ravimi valmistamiseks insuliiniresistentsuse sündroomi jadiabeedi raviks

Info

Publication number
EE200300551A
EE200300551A EEP200300551A EEP200300551A EE200300551A EE 200300551 A EE200300551 A EE 200300551A EE P200300551 A EEP200300551 A EE P200300551A EE P200300551 A EEP200300551 A EE P200300551A EE 200300551 A EE200300551 A EE 200300551A
Authority
EE
Estonia
Prior art keywords
adenosine
analogues
medicament
manufacture
treatment
Prior art date
Application number
EEP200300551A
Other languages
English (en)
Estonian (et)
Inventor
Herling Andreas
J�hne Gerhard
P. Maguire Martin
P. Spada Alfred
R. Myers Michael
Mi Choi-Sledeski Yong
W. Pauls Heinz
R. Ewing William
Original Assignee
Aventis Pharma Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deutschland Gmbh filed Critical Aventis Pharma Deutschland Gmbh
Publication of EE200300551A publication Critical patent/EE200300551A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
EEP200300551A 2001-05-14 2002-05-14 Adenosiini ja selle analoogide kasutamine ravimi valmistamiseks insuliiniresistentsuse sündroomi jadiabeedi raviks EE200300551A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01111651A EP1258247A1 (en) 2001-05-14 2001-05-14 Adenosine analogues for the treatment of insulin resistance syndrome and diabetes
PCT/EP2002/005301 WO2002092093A1 (en) 2001-05-14 2002-05-14 Adenosine analogues for the treatment of the insulin resistance syndrome and diabetes

Publications (1)

Publication Number Publication Date
EE200300551A true EE200300551A (et) 2004-02-16

Family

ID=8177414

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300551A EE200300551A (et) 2001-05-14 2002-05-14 Adenosiini ja selle analoogide kasutamine ravimi valmistamiseks insuliiniresistentsuse sündroomi jadiabeedi raviks

Country Status (23)

Country Link
US (1) US20030176390A1 (xx)
EP (2) EP1258247A1 (xx)
JP (1) JP2004533448A (xx)
KR (1) KR20040002962A (xx)
CN (1) CN1518450A (xx)
BG (1) BG108356A (xx)
BR (1) BR0209650A (xx)
CA (1) CA2447408A1 (xx)
CO (1) CO5540288A2 (xx)
CZ (1) CZ20033079A3 (xx)
EA (1) EA007253B1 (xx)
EE (1) EE200300551A (xx)
HR (1) HRP20030928A2 (xx)
HU (1) HUP0400464A3 (xx)
IL (1) IL158794A0 (xx)
MX (1) MXPA03010336A (xx)
NO (1) NO20035056D0 (xx)
NZ (1) NZ529390A (xx)
PL (1) PL364573A1 (xx)
SK (1) SK14052003A3 (xx)
WO (1) WO2002092093A1 (xx)
YU (1) YU90203A (xx)
ZA (1) ZA200308777B (xx)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200500281A (es) * 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0500785D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
GB0607953D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607948D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607950D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607944D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
AR060607A1 (es) 2006-04-21 2008-07-02 Novartis Ag Derivados de purina,composiciones farmaceuticas que los contienen, metodo de preparacion y usos en enfermedades obstructivas o inflamatorias de las vias respiratorias.
EP1889846A1 (en) 2006-07-13 2008-02-20 Novartis AG Purine derivatives as A2a agonists
EP1903044A1 (en) * 2006-09-14 2008-03-26 Novartis AG Adenosine Derivatives as A2A Receptor Agonists
MX2009004991A (es) * 2006-11-10 2009-05-20 Novartis Ag Derivados de monoacetato de ciclopenteno-diol.
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2009131196A1 (ja) * 2008-04-24 2009-10-29 武田薬品工業株式会社 置換ピロリジン誘導体およびその用途
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8729994D0 (en) * 1987-12-23 1988-02-03 Glaxo Group Ltd Chemical compounds
US5055569A (en) * 1989-10-19 1991-10-08 G. D. Searle & Co. N-(6)-substituted adenosine compounds
HUT61567A (en) * 1990-12-07 1993-01-28 Sandoz Ag Process for producing new pharmaceutical compositions comprising 2'-o-alkyladenosine derivatives and for producing 6-cyclohexyl-2'-o-methyladenosinehydrate
US6376472B1 (en) * 1996-07-08 2002-04-23 Aventis Pharmaceuticals, Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
UA51716C2 (uk) * 1996-07-08 2002-12-16 Авентіс Фармасьютікалз Продактс Інк. Сполуки, що мають гіпотензивну, кардіопротекторну, анти-ішемічну та антиліполітичну властивості, фармацевтична композиція та способи лікування
GB9723590D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
US6258793B1 (en) * 1999-12-03 2001-07-10 Cv Therapeutics, Inc. N6 heterocyclic 5′ modified adenosine derivatives

Also Published As

Publication number Publication date
NZ529390A (en) 2006-06-30
JP2004533448A (ja) 2004-11-04
ZA200308777B (en) 2006-04-26
YU90203A (sh) 2006-08-17
KR20040002962A (ko) 2004-01-07
EP1404338A1 (en) 2004-04-07
BG108356A (bg) 2004-12-30
CA2447408A1 (en) 2002-11-21
US20030176390A1 (en) 2003-09-18
HUP0400464A2 (hu) 2004-07-28
PL364573A1 (en) 2004-12-13
BR0209650A (pt) 2004-07-13
HRP20030928A2 (en) 2005-10-31
IL158794A0 (en) 2004-05-12
CO5540288A2 (es) 2005-07-29
MXPA03010336A (es) 2004-03-16
WO2002092093A1 (en) 2002-11-21
EP1258247A1 (en) 2002-11-20
EA200301231A1 (ru) 2004-04-29
CZ20033079A3 (cs) 2004-08-18
CN1518450A (zh) 2004-08-04
EA007253B1 (ru) 2006-08-25
HUP0400464A3 (en) 2007-03-28
SK14052003A3 (sk) 2004-07-07
NO20035056D0 (no) 2003-11-13

Similar Documents

Publication Publication Date Title
EE200300551A (et) Adenosiini ja selle analoogide kasutamine ravimi valmistamiseks insuliiniresistentsuse sündroomi jadiabeedi raviks
IL161155A0 (en) Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors
HK1087337A1 (en) Use of a hif-alpha stabilizing agent for the preparation of medicament for treatment of diabetes
EE05316B1 (et) Kristalliline antikolinergikum, meetod selle valmistamiseks ja selle kasutamine ravimi valmistamiseks
EE04414B1 (et) Tiotroopiumi sisaldav inhalatsioonipulber, meetodselle valmistamiseks ja selle kasutamine ravimi valmistamiseks
HRP20030949A2 (en) Pulmonary administration of chemically modified insulin
ATE347901T1 (de) Exendine zur glucagon suppression
EE04567B1 (et) Kristalliline monohdraat, meetod selle valmistamiseks ja selle kasutamine ravimi valmistamiseks
AU2003275301A8 (en) Drug delivery device having coated microprojections incorporating vasoconstrictors
AU2001279593A1 (en) A substance for use in a dietary supplement or for the preparation of a medicament for the treatment of non-insulin dependent diabetes mellitus, hypertension and/or the metabolic syndrome
WO2004050115A3 (en) Combination treatment using exendin-4 and thiazolidinediones
IL186426A0 (en) Use of nefopam and analogues thereof for the treatment of a syndrome characterised by chronic pain and fatigue
AU2003252182A8 (en) Therapeutic treatment for the metabolic syndrome and type 2 diabetes
EE200300398A (et) Isoksasoliini derivaat, selle saamine ja kasutamine depresioonivastase ravimi valmistamiseks ning seda sisaldav ravimkompositsioon
NO20043483L (no) Anvendelse av melagatran for fremstilling av et medikament for behandling av type 1 Diabetes mellitus
GB0606001D0 (en) Combination Of Cicletanine And An Oral Antidiabetic And/Or Blood Lipid-Lowering Agent For Treating Diabetes And Metabolic Syndrome
EE200200480A (et) Memnopeptiidühend, selle valmistamine ja raviotstarbeline kasutamine ning seda sisaldav farmatseutiline kompositsioon
HK1077216A1 (en) Use of thiazole derivatives for the manufacture ofa medicament for the treatment of chronic obstruc tive pulmonary disease
CL2004000399A1 (es) Compuestos derivados de 1,3-oxazol sustituidos de formula i; composicion farmaceutica; procedimiento de preparacion de la composicion farmaceutica; y su uso en el tratamiento de la resistencia a la insulina, dislipidemia diabetes mellitus.
GB0106465D0 (en) Treatment of the insulin resistance syndrome
GB0024093D0 (en) Treatment of the insulin resistance syndrome
GB0030649D0 (en) Treatment of the insulin resistance syndrome
BR0309375A (pt) Tratamento de sìndrome metabólica
WO2003075946A3 (en) Treatment of type i diabetes mellitus using growth hormone antagonist
WO2004082578A3 (en) Use of soluble cd14 for treatment of diseases